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RELEASE OF AVASTIN
Marketing regulations do not apply to individual
clinicians
Stephen J W Evans professor of pharmacoepidemiology
Medical Statistics, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
The “licensing” process generally works well to protect patients
from drug companies that promote ineffective or unsafe
products.1 This regulatory system is not intended to, and should
not, regulate clinical practice. In the UK the General Medical
Council has applied the industry regulation system to clinical
practice, thus discouraging, if not essentially forbidding,
clinicians from prescribing safe and effective products for which
drug companies, for profit reasons, have not applied for
marketing authorisation. Drug regulation does not, and should
not, take cost into account.
The EU directive and the court case that the GMC cites to defend
its guidance do not apply to individual pharmacies preparing
products for individual patients’ use and hence do not apply to
individual clinicians.2 The GMC and its lawyers should review
more carefully the EU law and understand the difference
between “unlicensed” and “outside themarketing authorisation.”
They should not apply law targeted at companies to individual
clinical practice. Then the National Institute for Health and Care
Excellence (not bound in law to recommend products only for
indications where there is a marketing authorisation) can make
untrammelled decisions on cost effective products. Sadly, the
drug industry continues to damage its public reputation by
opposing this thinking.3
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